Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy-Reference-Cited by-同舟云学术

Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy

Published:2018-11-19 Issue:2 Volume:26 Page:465-472
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Nakamura Yoshiaki,Yamanaka Takeharu,Chin Keisho,Cho Haruhiko,Katai Hitoshi,Terashima Masanori,Misawa Kazunari,Hirao Motohiro,Yoshida Kazuhiro,Oki Eiji,Sasako Mitsuru,Emi Yasunori,Bando Hideaki,Kawashima Yoshiyuki,Fukunaga Tetsu,Gotoh Masahiro,Ishibashi Takako,Shitara Kohei

Funder

A research funding from National Cancer Center Hospital East

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/article/10.1245/s10434-018-7063-8/fulltext.html

Reference21 articles.

1. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.

2. Bang Y-J, Kim Y-W, Yang H-K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.

3. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.